AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18947350 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative judgments
Number of subjects: 0
Study 15958836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (arm A)
Number of subjects: 130
Study 15958836 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (arm B)
Number of subjects: 130
Study 15958836 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (arm C)
Number of subjects: 130
Study 15958836 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (arm D)
Number of subjects: 130
Study 11834109 — intervention group
Group type: EXPERIMENTAL
Intervention: JS30 (30% of 1RM, n = 9)
Number of subjects: 26
Study 11834109 — intervention group
Group type: EXPERIMENTAL
Intervention: JS80 (80% of 1RM, n = 10)
Number of subjects: 26
Study 11834109 — intervention group
Group type: COMPARATOR
Intervention: C (Control group, n = 7)
Number of subjects: 26
Study 10520789 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 122
Study 10520789 — intervention group
Group type: COMPARATOR
Intervention: DCA
Number of subjects: 122
Study 7674270 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line combination therapy
Number of subjects: 0
Study 7674270 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 0
Study 2041384 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of 3 individualized interviews and written informative material.
Number of subjects: 244
Study 31510408 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-Gbit/s dual polarization Y-00 cipher with 218 phase levels
Number of subjects: 0
Study 31510408 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum (shot) noise masking
Number of subjects: 0
Study 29154056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga session (video-instructed)
Number of subjects: 24
Study 29154056 — intervention group
Group type: COMPARATOR
Intervention: Control condition (watching TV)
Number of subjects: 24
Study 26238568 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium (A millefolium) in teabag form for 3 days during 2 menstruation cycles
Number of subjects: 0
Study 26238568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23611083 — intervention group
Group type: EXPERIMENTAL
Intervention: TMT root treatment
Number of subjects: 62
Study 23611083 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 62
Study 21936251 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200 g daily containing Lactobacillus acidophilus La5 and Bifidobacterium animalis BB12, 10(7) CFU g(‐1) for each)
Number of subjects: 70
Study 21936251 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (200 g daily)
Number of subjects: 70
Study 21936251 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt
Number of subjects: 70
Study 21936251 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt
Number of subjects: 70
Study 20452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated HTO
Number of subjects: 19
Study 20452896 — intervention group
Group type: COMPARATOR
Intervention: Conventional HTO
Number of subjects: 19
Study 17370032 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported cholesterol awareness
Number of subjects: 39876
Study 17370032 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported cholesterol
Number of subjects: 39876
Study 16305268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid pelvic support belt
Number of subjects: 90
Study 16305268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrigid pelvic support belt
Number of subjects: 90
Study 16305268 — intervention group
Group type: COMPARATOR
Intervention: Exercise and advice
Number of subjects: 90
Study 12068419 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated stems
Number of subjects: 174
Study 12068419 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated surfaces
Number of subjects: 174
Study 9428852 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (350 micrograms/kg and 70 micrograms/kg)
Number of subjects: 45
Study 9428852 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium (64 micrograms/kg and 10 micrograms/kg)
Number of subjects: 45
Study 9428852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (200 micrograms/kg and 100 micrograms/kg)
Number of subjects: 45
Study 8559883 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape designed to increase concern
Number of subjects: 120
Study 8559883 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape designed to increase information
Number of subjects: 120
Study 8559883 — intervention group
Group type: COMPARATOR
Intervention: Control videotape of music
Number of subjects: 120
Study 8559883 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown means of transmission
Number of subjects: 120
Study 8559883 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 120
Study 8559883 — intervention group
Group type: EXPERIMENTAL
Intervention: Homosexual activity
Number of subjects: 120
Study 2227611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with phenylpropanolamine (PPA) 50 mg twice daily and estriol 4 mg once daily
Number of subjects: 29
Study 2227611 — intervention group
Group type: COMPARATOR
Intervention: Estriol 4 mg once daily
Number of subjects: 29
Study 374177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 7
Study 374177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 374177 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (neomycin and cathartics)
Number of subjects: 7
Study 31578015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 1,900 IU (0.2 mL) intravenously (IV group)
Number of subjects: 38
Study 31578015 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin 3,800 IU (0.4 mL) subcutaneously (SC group)
Number of subjects: 38
Study 31103547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 115
Study 31103547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 29318860 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 60
Study 29318860 — intervention group
Group type: COMPARATOR
Intervention: Control (electrodes attachment without electrical stimulation)
Number of subjects: 60
Study 25315260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day ALN
Number of subjects: 30
Study 25315260 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ALN
Number of subjects: 30
Study 25315260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 30
Study 23193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced article presenting claims both for/against an autism-vaccine link
Number of subjects: 320
Study 23193194 — intervention group
Group type: COMPARATOR
Intervention: Link claims only
Number of subjects: 320
Study 23193194 — intervention group
Group type: COMPARATOR
Intervention: No-link claims only
Number of subjects: 320
Study 23193194 — intervention group
Group type: COMPARATOR
Intervention: Non-health-related information
Number of subjects: 320
Study 21817116 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein (natural product extract)
Number of subjects: 0
Study 21817116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of baicalein by repeated injection
Number of subjects: 0
Study 21817116 — intervention group
Group type: COMPARATOR
Intervention: Control group (breast cancer cell line with short hairpin RNA against IRF‐1)
Number of subjects: 0
Study 19657202 — intervention group
Group type: EXPERIMENTAL
Intervention: AFA breathing therapy
Number of subjects: 0
Study 19657202 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 0
Study 16776706 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic dengue fever
Number of subjects: 0
Study 16776706 — intervention group
Group type: COMPARATOR
Intervention: Dengue haemorrhagic fever
Number of subjects: 0
Study 14976885 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (ICWM) therapeutic program
Number of subjects: 48
Study 14976885 — intervention group
Group type: COMPARATOR
Intervention: Western medical therapeutic program
Number of subjects: 48
Study 10899358 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine infusion
Number of subjects: 10
Study 10899358 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion of saline
Number of subjects: 10
Study 9024142 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily drinkers (>= 7 drinks per week)
Number of subjects: 22071
Study 9024142 — intervention group
Group type: COMPARATOR
Intervention: Reference group (< 1 drink per week)
Number of subjects: 22071
Study 8329004 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine monofluorophosphate (G-MFP) tablets
Number of subjects: 12
Study 8329004 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine monofluorophosphate (G-MFP) powder for oral use
Number of subjects: 12
Study 3553627 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric consultation team (GCT) consultation
Number of subjects: 185
Study 3553627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GCT consultation)
Number of subjects: 185
Study 29644914 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless tri-axial accelerometers measuring kinematics during drag flicks
Number of subjects: 0
Study 27225873 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus pulse dose AT-101
Number of subjects: 32
Study 27225873 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus metronomic dose AT-101
Number of subjects: 32
Study 27225873 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 32
Study 25524543 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) maintenance therapy
Number of subjects: 0
Study 25524543 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 0
Study 22772570 — intervention group
Group type: EXPERIMENTAL
Intervention: PediGuard
Number of subjects: 18
Study 22772570 — intervention group
Group type: COMPARATOR
Intervention: Standard probe
Number of subjects: 18
Study 22772570 — intervention group
Group type: EXPERIMENTAL
Intervention: PediGuard and Standard probe
Number of subjects: 18
Study 21360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to heavy metals (arsenic, cadmium, lead) in copper smelters
Number of subjects: 166
Study 21360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking smelters
Number of subjects: 166
Study 21360924 — intervention group
Group type: COMPARATOR
Intervention: Smoking persons from control group
Number of subjects: 166
Study 21360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to heavy metals
Number of subjects: 166
Study 21360924 — intervention group
Group type: COMPARATOR
Intervention: Tobacco smoke
Number of subjects: 166
Study 18535882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest gated SPECT with (99m)Tc-tetrofosmin
Number of subjects: 54
Study 16281491 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg + aspirin 325 mg (group 1)
Number of subjects: 211
Study 16281491 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg + aspirin 325 mg (group 2)
Number of subjects: 211
Study 16281491 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 211
Study 16281491 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 211
Study 11904653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC)
Number of subjects: 201
Study 11904653 — intervention group
Group type: COMPARATOR
Intervention: Control (no PAC)
Number of subjects: 201
Study 11904653 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC management decisions
Number of subjects: 201
Study 11904653 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 201
Study 10464060 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (13.5 mg/kg)
Number of subjects: 14
Study 10464060 — intervention group
Group type: EXPERIMENTAL
Intervention: NO inhalation (30 p.p.m)
Number of subjects: 14
Study 10464060 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 14
Study 8751032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg q.i.d. for 6 days)
Number of subjects: 8
Study 2210987 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 18
Study 2210987 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 18
Study 2210987 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study 631030 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (4.5 mg daily)
Number of subjects: 100
Study 631030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31899340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise training (50%-70% of heart rate reserve, 30-45 min, 3 sessions/week for 12 weeks)
Number of subjects: 31
Study 31899340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise training
Number of subjects: 31
Study 31899340 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 31
Study 29779161 — intervention group
Group type: EXPERIMENTAL
Intervention: Masivukeni mHealth application for standardized ART counselling
Number of subjects: 0
Study 29779161 — intervention group
Group type: EXPERIMENTAL
Intervention: Department of Health (DoH) support for Masivukeni
Number of subjects: 0
Study 26683599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic impedance monitoring (IIM) alarm turned on and diuretic dose increased by 50% for 1 week in the event of alarm sounding
Number of subjects: 80
Study 26683599 — intervention group
Group type: COMPARATOR
Intervention: Control group (IIM alarm turned off)
Number of subjects: 80
Study 23985625 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 300 mg twice daily
Number of subjects: 234
Study 23985625 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 600 mg once daily
Number of subjects: 234
Study 23985625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study 22440067 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive thinking about negatively valenced future events
Number of subjects: 108
Study 22440067 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive thinking about positively valenced future events
Number of subjects: 108
Study 22440067 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive thinking about neutrally valenced future events
Number of subjects: 108
Study 22440067 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive thinking (general)
Number of subjects: 108
Study 22440067 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative repetitive future thinking
Number of subjects: 108
Study 20613645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training program (CTP) including 5 sets of 8-5 repetition maximum (RM) half squat with 1 30-m sprint after each set.
Number of subjects: 26
Study 20613645 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performing only technical preparation.
Number of subjects: 26
Study 20613645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training program (CTP)
Number of subjects: 26
Study 20613645 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study 18410584 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin (n = 24)
Number of subjects: 45
Study 18410584 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication (n = 21)
Number of subjects: 45
Study 15838561 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 60
Study 15838561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12000008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx) 500 mg l(‐1) added to prime solution
Number of subjects: 25
Study 12000008 — intervention group
Group type: COMPARATOR
Intervention: Control group received only prime solution
Number of subjects: 25
Study 10811508 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + gemcitabine
Number of subjects: 34
Study 10811508 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + vinorelbine
Number of subjects: 34
Study 8670316 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1Ra 20 mg administered once, 3 times, or 7 times per week
Number of subjects: 175
Study 8670316 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1Ra 70 mg administered once, 3 times, or 7 times per week
Number of subjects: 175
Study 8670316 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1Ra 200 mg administered once, 3 times, or 7 times per week
Number of subjects: 175
Study 8670316 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on days rHuIL‐1Ra was not administered
Number of subjects: 175
Study 8670316 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1Ra (all doses) administered once per week during the maintenance phase
Number of subjects: 175
Study 1999097 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 13
Study 1999097 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-supplemented room air
Number of subjects: 13
Study 6660172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 50
Study 30632413 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (0.5 g·kg‐1·day‐1)
Number of subjects: 32
Study 30632413 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate beverage (0.5 g·kg‐1·day‐1)
Number of subjects: 32
Study 28570730 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic conformal radiotherapy (SCRT)
Number of subjects: 200
Study 28570730 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (ConvRT)
Number of subjects: 200
Study 25571332 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted locomotor training (Lokomat)
Number of subjects: 0
Study 25571332 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-spastic medication (tizanidine)
Number of subjects: 0
Study 25571332 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 22958957 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2774
Study 22958957 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 2774
Study 19934090 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin (Hb) of 9-10 g/dl
Number of subjects: 8209
Study 19934090 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin (Hb) > 13 g/dl
Number of subjects: 8209
Study 19934090 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin concentrations across the years 1999 to 2005
Number of subjects: 8209
Study 19934090 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, time on dialysis, and diabetes
Number of subjects: 8209
Study 18585510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed anticoagulation services (PMAS) follow-up
Number of subjects: 250
Study 18585510 — intervention group
Group type: COMPARATOR
Intervention: Physician follow-up
Number of subjects: 250
Study 18585510 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PMAS and physician)
Number of subjects: 250
Study 15860488 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses
Number of subjects: 58
Study 11931067 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case treatment
Number of subjects: 31
Study 11931067 — intervention group
Group type: COMPARATOR
Intervention: In-patient stay
Number of subjects: 31
Study 10076743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) and medication simultaneously (n = 9)
Number of subjects: 29
Study 10076743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) only (n = 6)
Number of subjects: 29
Study 10076743 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication while on a wait-list for CBT (n = 6)
Number of subjects: 29
Study 10076743 — intervention group
Group type: COMPARATOR
Intervention: No treatment while on a wait-list for CBT (n = 5)
Number of subjects: 29
Study 10076743 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent administration of CBT to those groups on the wait-list
Number of subjects: 29
Study 9395604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative ion treatment (2.7 x 10(6) ions/cm3)
Number of subjects: 25
Study 9395604 — intervention group
Group type: COMPARATOR
Intervention: Low-density negative ion treatment (1 x 10(4) ions/cm3)
Number of subjects: 25
Study 1954643 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-K tablets
Number of subjects: 107
Study 1954643 — intervention group
Group type: COMPARATOR
Intervention: Micro-K 10 Extencaps
Number of subjects: 107
Study 6835735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother‐Child Separately
Number of subjects: 0
Study 6835735 — intervention group
Group type: COMPARATOR
Intervention: Mother‐Child Together
Number of subjects: 0
Study 6835735 — intervention group
Group type: COMPARATOR
Intervention: Child Alone
Number of subjects: 0
Study 6835735 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with highest initial blood pressures
Number of subjects: 0
Study 30223315 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone 8 mg (IV)
Number of subjects: 80
Study 30223315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal dexamethasone 8 mg (IP)
Number of subjects: 80
Study 29884319 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a care pathway
Number of subjects: 514
Study 29884319 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 514
Study 26831174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric combination of magnesium sulphate and ropivacaine by the spinal route
Number of subjects: 20